X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (941) 941
index medicus (789) 789
diabetes mellitus, type 2 - drug therapy (621) 621
male (606) 606
endocrinology & metabolism (545) 545
type 2 diabetes (524) 524
hypoglycemic agents - therapeutic use (496) 496
female (485) 485
diabetes (454) 454
animals (430) 430
sulfonylurea (418) 418
metformin (416) 416
middle aged (362) 362
insulin (333) 333
sulfonylurea compounds - therapeutic use (331) 331
glucose (296) 296
aged (279) 279
glycemic control (271) 271
pharmacology & pharmacy (262) 262
hypoglycemic agents - adverse effects (237) 237
hypoglycemic agents - administration & dosage (228) 228
diabetes mellitus, type 2 - blood (223) 223
metformin - therapeutic use (210) 210
hypoglycemic agents (206) 206
drug therapy, combination (205) 205
adult (201) 201
treatment outcome (199) 199
diabetes mellitus (195) 195
rats (194) 194
sulfonylureas (188) 188
diabetes therapy (187) 187
drug therapy (187) 187
hypoglycemic agents - pharmacology (171) 171
sulfonylurea receptor (169) 169
hypoglycemia (168) 168
blood glucose - metabolism (166) 166
thiazolidinediones - therapeutic use (162) 162
care and treatment (159) 159
mellitus (157) 157
double-blind (156) 156
analysis (152) 152
research (151) 151
glucagon-like peptide-1 (150) 150
glycated hemoglobin a - metabolism (150) 150
blood glucose - drug effects (142) 142
sulfonylurea receptors (142) 142
mice (139) 139
sulfonylurea compounds - pharmacology (139) 139
dextrose (136) 136
internal medicine (133) 133
sulfonylurea compounds - administration & dosage (131) 131
thiazolidinediones (130) 130
dipeptidyl-peptidase iv inhibitors - therapeutic use (124) 124
risk factors (120) 120
efficacy (119) 119
insulin - metabolism (118) 118
insulin - therapeutic use (118) 118
insulin secretion (118) 118
medicine, general & internal (118) 118
glibenclamide (117) 117
clinical trials (116) 116
safety (116) 116
exenatide (115) 115
hyperglycemia (115) 115
sulfonylurea compounds - adverse effects (114) 114
type 2 diabetes mellitus (114) 114
glycosylated hemoglobin (111) 111
insulin resistance (108) 108
potassium channels (108) 108
diabetes mellitus, type 2 - complications (105) 105
medicine & public health (105) 105
diabetes mellitus, type 2 - metabolism (102) 102
liraglutide (101) 101
dose-response relationship, drug (100) 100
glimepiride (100) 100
double-blind method (99) 99
therapy (99) 99
risk (93) 93
glyburide - pharmacology (92) 92
hypoglycemia - chemically induced (91) 91
pioglitazone (91) 91
biochemistry & molecular biology (88) 88
type-2 diabetes-mellitus (87) 87
mortality (86) 86
insulin-secretion (85) 85
potassium channels - drug effects (81) 81
studies (81) 81
metformin - administration & dosage (79) 79
patients (79) 79
peptides - therapeutic use (79) 79
rosiglitazone (79) 79
abridged index medicus (78) 78
association (78) 78
drugs (77) 77
pancreatic beta-cells (75) 75
dosage and administration (74) 74
management (73) 73
potassium channels - metabolism (73) 73
glucagon (71) 71
health aspects (71) 71
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1466) 1466
Japanese (3) 3
French (2) 2
German (2) 2
Hungarian (2) 2
Russian (2) 2
Chinese (1) 1
Danish (1) 1
Italian (1) 1
Korean (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Wang, B and Zhong, J and Lin, H and Zhao, Z and Yan, Z and He, H and Ni, Y and Liu, D and Zhu, Z
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2013, Volume 15, Issue 8, pp. 737 - 749
Aims Aside from lowering blood glucose, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) attract much attention because of their cardioprotective effects.... 
randomized trials | meta‐analysis | GLP‐1 | hypertension | Hypertension | GLP-1 | Randomized trials | Meta-analysis | GLYCEMIC CONTROL | meta-analysis | WEIGHT-LOSS | ANALOG LIRAGLUTIDE | OPEN-LABEL | TWICE-DAILY EXENATIDE | DRUG-NAIVE PATIENTS | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK-FACTORS | Cardiovascular Diseases - prevention & control | Humans | Hypertension - drug therapy | Male | Hypertension - blood | Cardiovascular Diseases - blood | Female | Blood Pressure - drug effects | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - analogs & derivatives | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Diabetic Angiopathies - blood | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Glucagon-Like Peptide-1 Receptor | Venoms - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Liraglutide | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Glucose metabolism | Peptides | Blood sugar | Blood pressure | Hypoglycemic agents | Confidence intervals | Medical research | Drug therapy
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 2015, Volume 110, Issue 1, pp. 26 - 37
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2012, Volume 14, Issue 10, pp. 910 - 917
Aims To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal... 
basal insulin | type 2 diabetes | Asian patients | GLP‐1 | lixisenatide | Type 2 diabetes | Basal insulin | GLP-1 | Lixisenatide | METFORMIN | GLYCEMIC CONTROL | EFFICACY | SAFETY | EXENATIDE | PEPTIDE-1 ANALOG LIRAGLUTIDE | HYPERGLYCEMIA | ENDOCRINOLOGY & METABOLISM | JAPANESE PATIENTS | WEIGHT | GLIBENCLAMIDE | Japan - epidemiology | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Sulfonylurea Compounds - pharmacology | Philippines - epidemiology | Postprandial Period | Aged, 80 and over | Adult | Female | Hypoglycemia - blood | Sulfonylurea Compounds - administration & dosage | Drug Therapy, Combination | Republic of Korea - epidemiology | Body Mass Index | Insulin - pharmacology | Double-Blind Method | Drug Administration Schedule | Blood Glucose | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Taiwan - epidemiology | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Clinical trials | Blood sugar | Insulin | Diabetes therapy | Original
Journal Article
American Health and Drug Benefits, ISSN 1942-2962, 06/2017, Volume 10, Issue 4, pp. 178 - 187
It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2... 
Type 2 diabetes | DPP-4 inhibitors | Semaglutide | Exenatide | Insulin | Lixisenatide | Dulaglutide | GLP-1 receptor agonists | Sulfonylureas | Incretin-based therapy | Albiglutide | Diabetes | Metformin | Liraglutide | liraglutide | insulin | Clinical | metformin | dulaglutide | albiglutide | incretin-based therapy | type 2 diabetes | lixisenatide | sulfonylureas | diabetes | exenatide | semaglutide
Journal Article
ANNALS OF PHARMACOTHERAPY, ISSN 1060-0280, 05/2012, Volume 46, Issue 5, pp. 710 - 717
OBJECTIVE: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. DATA SOURCES: PubMed was... 
liraglutide | METFORMIN | incretins | GLYCEMIC CONTROL | SULFONYLUREA | HEALTHY-SUBJECTS | EXENATIDE EXENDIN-4 | glucagon-like peptide-1 | PHARMACODYNAMICS | TREATED PATIENTS | gastric emptying | albiglutide | type 2 diabetes | PHARMACOKINETICS | lixisenatide | interaction | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | exenatide
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2016, Volume 18, Issue 8, pp. 755 - 765
Aims To evaluate the comparative cardiovascular disease (CVD) safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in head‐to‐head comparisons with... 
cardiovascular disease | DPP‐4 inhibitor | GLP‐1 analogue | insulin therapy | sulphonylureas | pharmaco‐epidemiology | pharmaco-epidemiology | DPP-4 inhibitor | GLP-1 analogue | METAANALYSIS | EVENTS | ADMINISTRATIVE DATA | EXENATIDE | RISK | CLINICAL-TRIALS | DISEASE | ENDOCRINOLOGY & METABOLISM | OUTCOMES | TYPE-2 DIABETES-MELLITUS | ASSOCIATION | Myocardial Infarction - epidemiology | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Diabetes Mellitus, Type 2 - metabolism | Cardiovascular Diseases - epidemiology | Adult | Female | Myocardial Revascularization - statistics & numerical data | Stroke - epidemiology | Retrospective Studies | Drug Therapy, Combination | Databases, Factual | Hypoglycemic Agents - therapeutic use | Sulfonylurea Compounds - therapeutic use | Angina, Unstable - epidemiology | Proportional Hazards Models | Propensity Score | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Cohort Studies | Type 2 diabetes | Safety and security measures | Glucagon | Analysis | Glycosylated hemoglobin | Epidemiology | Insulin | Heart attack | Confidence intervals | Heart attacks
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 7, pp. 1797 - 1805
Journal Article